14^th World Drug Delivery Summit May 29-30, 2020 London, UK

Track 1 : Drug repurposing to treat Viruses: COVID-19

Drug repurposing is a methodology for making more value from an existing drug by targeting diseases by focusing on infections other than that for which it was initially proposed, For instance, teicoplanin, oritavancin, dalbavancin and monensin are affirmed antibiotics that have been appeared to inhibit corona- and other viruses in the research facility. The researchers reviewed information on the discovery and development of wide-spectrum antiviral agents (BSAAs), which are drugs that target viruses from two or more different viral families. They condensed what they found for 120 drugs that had just been demonstrated to be ok for people use and made a database, which is uninhibitedly available Thirty-one of these were found by the researchers to be possible candidates for prophylaxis and treatment of the COVID-19 infections. The researchers also found that clinical investigations have recently begun of five possible drug candidates to treat the virus that causes COVID-19.

Track 2: Advanced Drug Delivery Systems

Advanced drug delivery systems (DDS) involves indubitable advantages for drug administration. Over the past three decades, new proposals have been recommended for the evolution of novel carriers for drug delivery. General concepts and emerging research in this field based on multidisciplinary proposals aimed at generate customized treatment for a broad range of highly universality diseases (e.g., cancer and diabetes). This review is made of two parts. The first part supply an overview on currently available drug delivery technologies counting a brief history on the development of these systems and some of the research strategies applied. The second part supply information about the most advanced drug delivery devices using stimuli-responsive polymers.

Track 3: Drug Targeting and Design

Target drug delivery system is a marked form of drug delivery system. The therapeutic response of a drug based upon the interaction of drug molecules with cell on cell membrane interconnected biological events at receptor sites in concentration dependent manner. Targeted drug delivery entail for selective and functional localization of pharmacologically active moiety at pre recognized (preselected) target in therapeutic concentration, while moderate its entrance to non-target normal cellular linings, thus reduce toxic effects and increase therapeutic index. Targeting of drugs to marked cells and tissues of the body without their becoming a part of systemic circulation is a tremendous novel idea. If a drug can be distribute in a form such that it reaches the receptor sites in adequate concentration without interrupting in extraneous tissue cells.

Track 4: Drug Delivery Technologies

Pharmaceutical drug delivery technologies magnify drug absorption, efficacy, and patient experience. Taste maskers increase the commercial viability of your pharmaceutical products by neutralizing the strong, bitter tastes of certain oral medical formulations. “A growing number of companies are investing in technologies counting  pen injectors , dry powder inhalers (DPIs),  auto injectors, nasal sprays, buccal films, intraocular implants, orally disintegrating tablets (ODT), and infusion pumps, numerous  of which are draft for use with biologic drugs. The evolutions in these areas are a result of their proven technology, high dose efficacy, and their capability to offer magnify patient comfort and compliance.”

Track 5: Nanotechnology for better Drug Deliverability

Development and optimization of drug delivery approaches based in nanoparticles concerns the early detection of cancer cells and/or specific tumour biomarkers, and the enhancement of the efficacy of the treatments applied. The usage of ideal nano-drug delivery system is obstinate principally depend on the biophysical and biochemical properties of the targeted drugs being adopt for the treatment. Thus, using green nanoparticles for drug delivery can reduce the side-effects of the medications. Moreover, naturalizations in nanostructures hydrophobicity, size, surface changes and shape, can further magnify the bioactivity of these nanomaterials.

Track 6: Novel Drug Delivery

Novel Drug delivery System (NDDS) developed in order to reduce drug degradation, drug adverse effect, and in order to maximize the drug bioavailability (amount of drug available at site targeted region).  Site specific drug delivery may be active or passive process. Novel Drug Delivery System is a fusion of advanced skills and advanced dosage forms which are far fitter than conventional dosage forms. Evolution of an existing drug molecule from a conventional form to a novel delivery system can importantly improve its presentation in terms of patient acquiescence, security and potency.  In the form of a Novel Drug Delivery System a live drug molecule can get a new life.

Track 7: Drug Discovery and Development

Drug discovery is a versatile process by which new therapeutics are expanded. From initial target identification to late stage clinical trials, a wide range of scientific personnel are required from across the biosciences and beyond. Biologists, protein scientists, medicinal chemists, pharmacologists, toxicologists and computational scientists all have key roles to play. This process is essential as it is the means by which new drugs, frequently with novel modes of action, become accessible to patients.

Track 8: Cellular Targeting and Intracellular Delivery

Targeted drug delivery to diseased tissues suggests keen benefits for therapy, such as enlarge potency and decrease side effects. The evolution of targeted drug delivery systems is handling by various drug design concerns, election of suitable cell culture models, and analytical tools for their observation. Targeting cells depend on the hardware encoding biological information. Whereas a practical benefit of the genetic code has not been announce until now, that of the peptide code constituted by antibody-based conceptions entered clinical trials and few products are already on the market. Recently, usage of the sugar code also became evident as a promising alternative.

Track 9: Anti-Cancer Drug Delivery Agents

Most explored approaches to developing cell-based Anti Cancer drug delivery systems (DDSs) are encapsulation of the drug into the cells, cell surface modification, genetic modification of cells to secrete desired therapeutic proteins, and generating new biosynthetic systems. Tumor-tropism of mesenchymal stem cells (MSCs), as reveal in many studies, can be incorporate with expropriate engineering with anticancer genes to authorize their utilization in anticancer therapy. Furthermore, MSCs can be filled with nanoparticles (NPs), procure transport across the blood-brain barrier and accumulation of anticancer agent at the tumour site.

Track 10: Vaccine Drug Delivery Systems

Vaccines are determine as “preparations given to patients to induce immune reaction  dominant to the making of antibodies (humoral) or cell-mediated reaction that will help in attacking infectious agents or non-infectious state such as malignancies”. Sub-unit vaccines though exceptionally selective and specific in reacting with antibodies often fail to show such reactions in circumstances such as shifts in epitopic identification center of antibody and are poorly immunogenic. Active immunization is process of enlarge retardation to infection where by microorganism or product of their pursuit act as a antigens and restorate certain body cell produce a antibodies with particular defensive capacity.

Track 11: Peptides and Protein Drug Delivery

Peptide and Protein drug delivery system are known as Novel drug Delivery System. Proteins and peptides are the most abundant components of biological cells. They exist functioning such as enzymes, hormones, structural element and immunoglobulin. The twenty various naturally transpire amino acids join with each other by peptide bonds and construct polymers mentioned to peptides and proteins. Although the variance between peptides and proteins are peptide having less than 20 amino acids, having a molecular weight less than 5000, while a protein contain 50 or more amino acids and its molecular weight lies high this value. Many of pharmaceutical proteins and peptides are engross IM, IV and Subcutaneous route of Absorption, but the oral route is more appropriate for absorption of protein as collate to other.

Track 12: Therapeutic Drug Carrier Systems

Therapeutic uses of a diverse of drug carrier systems have compelling effect on the treatment and possible heal of various chronic diseases, including Alzheimer, parkinsons, diabetes mellitus, cancer , psoriasis, , rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific attempts in these areas a versatile, including the biological, medical, physical, pharmaceutical, biological materials, and engineering fields. Drug carrier systems are now as important as the drug itself. Controlled release supply extends delivery of a drug while sustaining its blood concentration within therapeutic limits.

Track 13: Routes of Drug Administration

Advances in drug formulations and inventive routes of administration have been made. Our comprehension of drug transport across tissues has enlarged. These transformation have frequently caused in enhance patient constancy to the therapeutic regimen and pharmacologic response. The administration of drugs by transdermal or transmucosal routes provides the prevalence of being relatively painless. Also, the potential for immense compliance in a variety of clinical situations exists, frequently precluding the obligation to initiate intravenous access, which is a specific assistance for children. This report focuses on the advantages and disadvantages of alternative routes of drug administration. Concerns of specific significance in the protection of pediatric patients, particularly elements that could guide to drug-related toxicity or adverse responses, are emphasized.

Track 14: Pharmaceutical Formulation Technologies

Pharmaceutical formulations are combination of the pharmaceutically active ingredient and determine inactive ingredients. Solution formulations that are used for injectable dosage forms commonly have some inactive ingredients—such as buffering agents, water, co-solvents, and pH-adjusting agents. As a consequence, they are copious easy to formulate collate to some of the semisolid formulations used for topical administration. A pharmaceutical formulation is made of various formulation factors and process variables. Quantitative model-based pharmaceutical formulation includes initiating mathematical relations enclosed by the formulation variables and the emerge responses and extend the formulation cases.

Track15: Drug Delivery through Blood-Brain Barrier (BBB)

The brain is shielded and segregated from the normal circulation by a highly adequate blood-brain barrier. This is characterised by relatively impermeable endothelial cells with tight junctions, enzymatic activity and active efflux transport systems. Therefore the blood-brain barrier is layout to allow discriminatory carrier of molecules that are important for brain function. This builds a extensive protest for the treatment of central nervous system diseases compelling therapeutic levels of drug to get into the brain. Some small lipophilic drugs diffuse across the blood-brain barrier- sufficiently well to be efficacious. However, many potentially useful drugs are excluded.

Track 16: Controlled Released Technologies

Controlled drug release and consequent ecological are important for evolving fortunate formulations. The method of delivery can be the variation enclosed by a drug’s accomplishment and failure, as the selection of a drug is frequently persuaded by the way the medicine is administered. Sustained (or continuous) release of a drug includes polymers that deliver the drug at a controlled rate due to dispersion out of the polymer or by degradation of the polymer over time. Pulsatile release is frequently the selected method of drug delivery, as it enclosure mimics the way by which the body generally produces hormones such as insulin. It is accomplished by using drug-carrying polymers that react to particular stimuli (e.g., exposure to light, changes in pH or temperature).

 

Track 17: Transdermal and Intradermal Drug Delivery Systems

Bio adhesive liposomes contain levonorgestrel as controlled drug delivery system has been investigated. Mesophasic proliposomal system for levonorgestral was processed. The vesicles were predominantly unilamellar and some were multilamellar. Deliver was of zero order kinetics. Alcohol as compared to oils had tremendous influence on transdermal flux. In vivo studies demonstrate that important lag phase was notice before the therapeutic levels were reached reveal the specification for a loading dose. This pro liposomes system was begin to be superior to PEG-based ointment system. Liposomal reservoir system containing local anaesthetic benzocaine was evolved for controlled and localized delivery via topical route. The liposomal suspension was included into an ointment and gel base.

Track 18:  Biopharmaceutics and Biologic Drugs:

Pharmaceutical biotechnology has been display therapeutic accomplishment never attain with standard drug molecules. Accordingly biopharmaceutical products are presently well-established in clinic and the evolution of new ones is anticipated. These products comprise mainly therapeutic proteins, although nucleic acids and cells are also included. However, as stated to their sensitive molecular structures, the systematic delivery of biopharmaceuticals is challenging. Various delivery systems (e.g. Micro particles and nanoparticles) made of several materials (e.g. polymers and lipids) have been analysed and determine tremendous outcomes, such as: high cellular transfection ability for nucleic acids, increased proteins, cell targeting, and peptides bioavailability, improved immune response in vaccination, and viability maintenance of microencapsulated cells, Drug implants. Biologic Drugs are genetically arisen from a living organism, such as a virus, protein, to maintain the body’s natural response to infections and diseases.

Track 19: Medical Devices for Drug Delivery

Medical devices layout for drug delivery through the pulmonary and nasal routes. These routes are of interest for local delivery, as in asthma, but also for rapid delivery of drugs to the system circulation and direct delivery to the central nervous system. Devices that report for particular anatomical and physiological features of the intranasal and pulmonary routes will be characterized. Drug delivery devices are specialized tools for the delivery of a drug or therapeutic agent via a particular route of administration. Such devices are used as bit of one or more medical treatments. Many in the industry have lengthy felt overly laden by what they acknowledge to be an unessential complicated approval process. Critics declare it impedes innovation and detain the opportunity of better health care. In order to help innovators import health care to the public.

Track 20: RNA Therapeutics

RNA and its molecular sibling, DNA (short for "deoxyribonucleic acid") are the main information carrying molecules in all living organisms. DNA is extremely stable. The recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field. RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of genetic, infectious and chronic diseases.

The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations.

 

The global market for drug delivery systems was valued at nearly $176.7 billion in 2020 and is expected to reach nearly $182 billion in 2021. BCC Research projects the market to grow to nearly $212.8 billion by 2023, and register a 5-year compound annual growth rate of 3.2% from 2020 to 2025.  The global pharmaceutical drug delivery market is split up into four major regions, namely, Europe, Asia Pacific, North America, and the remaining of the World. This study analyzes the $93.8 billion US drug delivery system industry. It presents historical demand data for the years 2000, 2005 and 2010, and forecasts for 2015 and 2020 by excipient (e.g., polymers, cellulose, minerals), product type (e.g., oral, parenteral, inhalation, implantable, transdermal) and application (e.g., central nervous system, respiratory, hormones, gastrointestinal).

The drug delivery market is forecast to reach USD 1,694.7 billion by 2023 from USD 1,244.4 billion in 2018, at a CAGR of 6.4% during the projected period. Growth in this market is mainly directed by the increase frequency of chronic diseases, growth in technological advancements and biologics market, and new product launches. On the other hand, the danger of needle stick injuries and the rising pricing pressure are anticipated to ultimatum market growth in the coming years. In addition, patients’ wellness has progresses substantially with ever improving mechanization and possibilities of massive breakthroughs in this field have propelled the drug delivery industry to a new height, and also in having an astounding growth in drug delivery systems for hormones and cardiology agents. The global market for advanced drug delivery system is expected to amount for the value of $196.4 billion by 2025 at 7.2% CAGR.

Drug delivery mention to technologies, formulations, approaches, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its required therapeutic effect. The market is currently estimated to be worth USD 18.5 billion for the year 2018 and is expected to reach USD 51.7 billion by the end of 2025. The CAGR during this period of the forecast is 22.78%. Currently, North America dominates the global market owing to the fact that there is greater awareness and increase per capita income. The USA is the biggest market in the world, followed by Canada. This escalation is developing the need to analyze, review and forecast the growth of the drug delivery devices market. Owing to the rapid evolution of the market in the use of injectable drug delivery technology, medical device companies that are able to launch new innovative equipment will be rewarded with huge benefits.